137 Stock Overview A biotechnology company, develops and commercializes medicines for immune-mediated diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Aldeyra Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Aldeyra Therapeutics Historical stock prices Current Share Price US$5.69 52 Week High US$5.79 52 Week Low US$2.52 Beta 1.35 1 Month Change 16.90% 3 Month Change 16.32% 1 Year Change 91.98% 3 Year Change 64.57% 5 Year Change 20.13% Change since IPO 14.98%
Recent News & Updates
Insufficient new directors Dec 30
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold €69k worth of stock Aug 15
New major risk - Share price stability Aug 12
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap Aug 08 See more updates
Insufficient new directors Dec 30
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold €69k worth of stock Aug 15
New major risk - Share price stability Aug 12
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap Aug 08
New minor risk - Profitability Aug 06
No longer forecast to breakeven Aug 06 Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Aug 02
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable Jun 20
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease Jun 15
Forecast to breakeven in 2026 May 22
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 09
No longer forecast to breakeven May 06
New minor risk - Profitability May 05
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024 Apr 23
New minor risk - Profitability Apr 03
No longer forecast to breakeven Apr 03
Forecast to breakeven in 2024 Mar 29
New minor risk - Profitability Mar 28
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease Mar 28
CEO, President & Director recently sold €532k worth of stock Mar 14
Forecast to breakeven in 2024 Mar 11
New minor risk - Profitability Mar 10
Forecast to breakeven in 2024 Mar 09
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis Dec 19
New minor risk - Profitability Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 28
New minor risk - Profitability Nov 03
New minor risk - Market cap size Oct 20
New minor risk - Profitability Oct 18
Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease Oct 17
Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc Sep 03
Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc Sep 01
Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc Aug 02
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough Jun 28
Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis Jun 16
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023 May 25
Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials Feb 18
Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease Feb 08
Forecast to breakeven in 2025 Feb 02
Insufficient new directors Feb 01
Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma Dec 22
Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial Dec 14
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Dec 03
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease Nov 30
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy Oct 07
Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA Sep 15
Insider recently bought €1.1m worth of stock Aug 04
Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial Jul 13
CEO, President & Director recently bought €57k worth of stock Jun 28
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Tranquility-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease Jun 09
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 26
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 25
Aldeyra Therapeutics Announces That Post-Hoc Analysis Using Computer Automated Grading of Phase 3 Tranquility Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap over Vehicle for Primary Endpoint of Ocular Redness May 19
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
Aldeyra Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 Tranquility-2 Trial in Patients with Dry Eye Disease Apr 06
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day Mar 30
No longer forecast to breakeven Mar 19 Aldeyra Therapeutics, Inc. Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa Mar 10
Forecast to breakeven in 2024 Feb 24
Aldeyra Therapeutics, Inc. Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model Feb 02
Forecast to breakeven in 2024 Jan 25
Aldeyra Therapeutics, Inc Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra Jan 12
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Jan 05
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease Dec 21
Aldeyra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Apr 30
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 Invigorate Clinical Trial of Reproxalap in Allergic Conjunctivitis Apr 28
Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design Feb 05
Aldeyra Therapeutics, Inc. Announces Retirement of Jesse I. Treu from the Board of Directors Jan 26
Aldeyra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $65.000007 million. Jan 15
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease Jan 08
New 90-day low: €5.30 Jan 06
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis Dec 19
Aldeyra Announces First Patient Enrolled in the Phase 3 Tranquility Trial of Reproxalap for the Treatment of Dry Eye Disease Dec 10
Aldeyra Therapeutics, Inc. Updates on Its Clinical-Stage Projects Nov 07
New 90-day high: €6.90 Oct 16 Aldeyra Therapeutics, Inc. announced that it has received $8.960649 million in funding from Domain Associates, L.L.C., Johnson & Johnson Innovation - JJDC, Inc.
New 90-day high - €6.50 Aug 06
Aldeyra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $19.466534 million. Jul 17 Shareholder Returns 137 DE Biotechs DE Market 7D 11.0% 2.3% 0.5% 1Y 92.0% -2.6% 15.3%
See full shareholder returns
Return vs Market: 137 exceeded the German Market which returned 15.3% over the past year.
Price Volatility Is 137's price volatile compared to industry and market? 137 volatility 137 Average Weekly Movement 9.1% Biotechs Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 137's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 137's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Show more Aldeyra Therapeutics, Inc. Fundamentals Summary How do Aldeyra Therapeutics's earnings and revenue compare to its market cap? 137 fundamental statistics Market cap €345.94m Earnings (TTM ) -€43.37m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 137 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$44.80m Earnings -US$44.80m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 00:18 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Aldeyra Therapeutics, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Keay Nakae Ascendiant Capital Markets LLC Esther Lannie Hong Berenberg Thomas Shrader BTIG
Show 18 more analysts 
